ATAD2B

Across TCGA pan-cancer cohorts, ATAD2B Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ATAD2B data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATAD2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATAD2B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, HNSC, and UCEC are the cancer types where ATAD2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.160	0.770	<.001	27	view →
HNSC	OS	Median	II,III,IV	0.058	0.712	<.001	24	view →
UCEC	DFS	Median	III,IV	0.885	0.518	.015	16	view →
TGCT	DFS	Median	All	0.014	0.837	<.001	6	view →
CESC	OS	Median	IV	0.095	0.592	.004	6	view →
SARC	DFS	Median	All	0.038	0.591	<.001	6	view →
PAAD	DFS	Median	All	0.100	0.505	.004	6	view →
ESCA	DFS	Median	All	0.098	0.533	.003	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ATAD2B–LUAD (DFS)

Open the LUAD breakdown →